Key Highlights

  • Flyte Aviation (NYSEAMERICAN:VJET) reported Q3 Revenue of USD 1,838 thousand for the quarter ended Sept 30, 2026, against nil a year earlier.
  • Net loss was USD 15,121 thousand versus USD 2,344 thousand, including a noncash USD 12.5 million Impairment on Assets held for sale.
  • Loss from continuing operations was USD 1,853 thousand, compared with USD 1,235 thousand in the prior-year quarter.
  • Cash and cash equivalents were USD 2,393 thousand, with a Working Capital Deficit of USD 3.2 million and substantial doubt about continuing as a going concern.

Private Aviation Revenue Begins After the FLYTE Acquisition

Flyte Aviation (NYSEAMERICAN:VJET) filed its Quarterly Report on Nov 16, 2026 for the period ended Sept 30, 2026. The company was formerly Catheter Precision, and effective Oct 5, 2026 it changed its name and its NYSE American ticker from VTAK to VJET. It acquired 19.98% of FLYTE from SEG Jets under an agreement dated Feb 6, 2026, then the remaining 80.02% on Mar 9, 2026, for a total purchase price of USD 14,753 thousand. FLYTE operates regional private jet charter with a leased fleet of Cirrus Vision jets and charter brokerage, based in Farmingdale, New York. Third-quarter revenue was USD 1,838 thousand with cost of revenues of USD 1,514 thousand, leaving Gross Profit of USD 324 thousand. Nine-month revenue was USD 2,771 thousand, and one customer accounted for 14% of third-quarter revenues.

A USD 12.5 Million Impairment Drives the Net Loss

In September 2026 the company classified its VIVO and LockeT cardiac businesses as discontinued operations held for sale. Measuring that group at Fair Value less costs to sell produced a noncash impairment loss of about USD 12.5 million. Loss from discontinued operations was USD 13,268 thousand in the quarter, which pushed the net loss to USD 15,121 thousand against USD 2,344 thousand a year earlier. Selling, general and administrative expenses rose to USD 2,780 thousand from USD 1,191 thousand, and operating loss was USD 2,456 thousand. Nine-month net loss reached USD 20,117 thousand compared with USD 11,847 thousand.

Cash of USD 2.4 Million and a Going-Concern Warning

Cash and cash equivalents were USD 2,393 thousand at Sept 30, 2026, up from USD 88 thousand at Dec 31, 2025. The company raised about USD 18.7 million gross in nine months from common stock, Series C Convertible Preferred Stock and Warrant exercises, and used USD 10.2 million of cash in operating activities. Accumulated deficit was USD 329.6 million. Investors agreed in October to buy another USD 2.05 million of Series C-4 Convertible Preferred Stock. A 1-for-10 Reverse Stock Split took effect on Oct 5, 2026, and per share figures are restated.

Where Things Stand

Flyte Aviation (NYSEAMERICAN:VJET) posted a USD 15.1 million quarterly loss mainly because its former medical device businesses were written down as it shifted toward private aviation. The impairment of about USD 12.5 million is noncash, and loss from continuing operations was a smaller USD 1,853 thousand. On Nov 1, 2026, the company entered a non-binding letter of intent to sell the VIVO and LockeT businesses, and the filing says there is no assurance the sale will be completed or of its amount or timing. Cash on hand was USD 1.5 million as of Nov 10, 2026, which management does not expect to be enough to fund operations. Goodwill stood at USD 12,161 thousand and intangible assets at USD 4,038 thousand, with no impairment found in a qualitative review.